Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 11/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682165 | 1.00 | FDFT1 (0.45) | FDFT1ALDH1A1MAPTLPAR1NPC1 | |
| SCHEMBL8102417 | 0.90 | FDFT1 (0.49) | FDFT1ALDH1A1MAPTLPAR1MEN1 | |
| SCHEMBL8561718 | 0.82 | FDFT1 (0.47) | FDFT1ALDH1A1MAPTLPAR1MEN1 | |
| SCHEMBL8561726 | 0.82 | FDFT1 (0.47) | FDFT1ALDH1A1MAPTLPAR1MEN1 | |
| SCHEMBL8110836 | 0.81 | FDFT1 (0.46) | FDFT1LPAR1 | |
| SCHEMBL4287472 | 0.79 | FDFT1 (0.42) | FDFT1ALDH1A1 | |
| SCHEMBL8560596 | 0.79 | LPAR1 (0.47) | FDFT1ALDH1A1MAPTLPAR1NPC1 | |
| SCHEMBL8566775 | 0.79 | LPAR1 (0.47) | FDFT1ALDH1A1MAPTLPAR1NPC1 | |
| SCHEMBL8567301 | 0.79 | LPAR1 (0.47) | FDFT1ALDH1A1MAPTLPAR1NPC1 | |
| SCHEMBL4121857 | 0.78 | TAS1R3 (0.44) | ALDH1A1MAPTLPAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088416-A1 | DEUTERIUM-ENRICHED LAPAQUISTAT | PROTIA, LLC (US) | 2009-04-02 | — | — | US | disclosed |
| US-20080227770-A1 | Benzoxazepine Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1097928-B1 | 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-ones as anti-hyperlipidemics | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20080153801-A1 | Benzoxazepine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-11 | — | — | US | disclosed |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-11 | — | — | US | disclosed |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-11 | — | — | US | disclosed |
| US-20070117787-A1 | Benzoxazepine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-05-24 | — | — | US | disclosed |
| EP-1753752-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| EP-1650201-A1 | BENZOXAZEPINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005121133-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-20040072819-A1 | Benzoxazepine compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-04-15 | — | — | US | disclosed |
| US-6613761-B1 | (3R,5S)-N- methanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl) -1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4, 1-benzoxazepine-3-acetamide, used as antilipemic agents and enzyme inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| EP-0862562-B1 | BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS LIPID LOWERING AGENTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-1097928-A1 | 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-ones as anti-hyperlipidemics | Takeda Chemical Industries, Ltd. (JP) | 2001-05-09 | — | — | EP | disclosed |
| US-6110909-A | SQUALENE SYNTHETASE INHIBITING ANTILIPEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088416-A1 | DEUTERIUM-ENRICHED LAPAQUISTAT | LPXN, SLC10A2, SLC10A1 | FDFT1 778/4885ALDH1A1 1771/4885MAPT 2088/4885 |
| US-20070117787-A1 | Benzoxazepine compounds, their production and use | NR1H2, APOB, CETP | FDFT1 1208/4885ALDH1A1 2601/4885MAPT 3797/4885 |
| US-20040072819-A1 | Benzoxazepine compounds, their production and use | CES1, CETP, CYP46A1 | FDFT1 709/4885ALDH1A1 1529/4885MAPT 3925/4885 |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | NAAA, CPS1, COASY | FDFT1 1957/4885ALDH1A1 1472/4885MAPT 3828/4885 |
| US-20080227770-A1 | Benzoxazepine Compound | NR1H2, SQLE, NR1H3 | FDFT1 15/4885ALDH1A1 1170/4885MAPT 4191/4885 |
| US-20080153801-A1 | Benzoxazepine compounds, their production and use | CETP, PCSK9, LPL | FDFT1 841/4885ALDH1A1 2217/4885MAPT 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.